Continuous disclosure obligations might not be definitive enough and maybe we are to assume that Tox studies have commenced but further to this, continuous disclosure obligations will need to be adhered to prior to, or at time of ann results thereof
Ann: Full size deoxymab PAT-DX3 crosses the blood brain barrier, page-82
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |